Ascletis Pharma reports increase in issued shares after option exercises

Ascletis Pharma Inc. (HKEX:1672) announced an increase in its issued shares through a Next Day Disclosure Return filed on September 23, 2025. The company's opening balance of issued shares as of September 18, 2025, was 992,860,320, with 5,784,210 treasury shares. The total number of issued shares reached 998,644,530 by September 23, 2025.

The primary driver for this increase was the issuance of 169,000 new ordinary shares on September 23, 2025, at an issue price of HK$2.9 per share. This issuance resulted from eligible participants exercising share options granted under a scheme adopted on June 6, 2019. Additional issuances on the same date included 80,000 shares at HK$2.696, 20,000 shares at HK$3.932, and 45,000 shares at HK$1.448, all stemming from share option exercises.

Concurrently, the company reported several share repurchases for cancellation, totaling 700,000 shares across various dates in April 2025, ranging from HK$4.8531 to HK$6.4567 per share. These repurchased shares are yet to be cancelled.